CAMBRIDGE, Mass., Sept. 22, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has been named by FierceBiotech as one of 2014's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. 

"Amid a great deal of ain't-it-cool science in microbiomics, Seres Health stands out for its focus and commitment to practical therapeutic development," says Damian Garde, editor of FierceBiotech. "With R&D veteran Roger Pomerantz at the helm, the company is at once moving toward the market with a potentially paradigm-changing treatment and developing a promising pipeline."

"We are honored to be recognized as one of the innovative companies selected for this year's 'Fierce 15'," said Dr. Roger J. Pomerantz, President, CEO and Chairman of Seres Health. "There is a critical need for therapies to treat important microbiome-driven diseases and Seres is focused on bringing the next breakthrough drugs to patients."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.  This is FierceBiotech's twelfth annual Fierce 15 selection.  A complete list of "Fierce 15" companies can be found online at www.fiercebiotech.com/fierce15. 

An internationally recognized daily report reaching a network of over 270,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.  Founded by Flagship VentureLabs™, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $20 million in funding to date. For more information, please visit www.sereshealth.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

CONTACTS:

Rebecca Friend
FierceBiotech
202-824-5050
rebecca@fiercemarkets.com

For Seres Health:  Emily Rossi
Ruder Finn
212.593.6431
flagship@ruderfinn.com

SOURCE Seres Health

RELATED LINKS
http://www.sereshealth.com